Dr. Yi Chen

H.C. Wainwright & Co.

Recent Articles

Miami Biopharma Sells Part of Business and Begins New Clinical Trial 01/02/2025

Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.

Healthcare Co. Exceeds Expectations in Performance 01/24/2024

Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.

Cryoablation System Gets Approved in Brazil 09/07/2023

The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.

777% Gain Implied in Analyst's Target Price on Biopharma Co. 06/14/2023

Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report.